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Abstract 
The standard treatment for retained placenta is manual removal whatever its subtype 
(adherens, trapped or partial accreta). Although medical treatment should reduce the risk of 
anesthetic and surgical complications, they have not been found to be effective. This may be 
due to the contrasting uterotonic needs of the different underlying pathologies. In placenta 
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adherens, oxytocics have been used to contract the retro-placental myometrium. However, if 
injected locally through the umbilical vein, they bypass the myometrium and perfuse directly 
into the venous system. Intravenous injection is an alternative, but exacerbates a trapped 
placenta. Conversely, for trapped placentas, a relaxant could help by resolving cervical 
constriction, but would worsen the situation for placenta adherens. This confusion over 
medical treatment will continue unless we can find a way to diagnose the underlying 
pathology. This will allow us to stop treating the retained placenta as a single entity and 
delivering targeted treatments.  
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Key Message 
Way through the confusion of medical treatment for the retained placenta.  
 
The scale of the problem 
 
Obstetric hemorrhage remains a leading cause of maternal death worldwide (1) and retained 
placenta (RP) is a significant contributor (2). The incidence appears to be related to 
intrapartum intervention as rates increase with both time and health system development (3). 
The rate currently in Europe is around 2-3%. If RP is not treated, it may lead to maternal 
death due to postpartum hemorrhage or sepsis. Historically, in the UK, RP led to the deaths 
of around 7 women per 100,000 births (4), and in modern African settings, with delayed 
access for manual removal, the case fatality rate remains around 1% (5). It is clear however, 
that many RPs will spontaneously deliver with time. Indeed, in the placebo arm of the largest 
randomized trial to date, 38% delivered spontaneously over the hour following recruitment 
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with 10% having blood loss of over 1000mls  (6) . Thus, there is a careful risk-benefit 
balance between waiting, which allows more spontaneous deliveries, and intervening to 
prevent blood loss and sepsis. It has been suggested that when considering PPH the optimal 
time for manual removal is 18 minutes, (7), but does not take into consideration the adverse 
medical, neonatal or psychological effects of manual removal of placenta. 
Herman et al first documented the ultrasound findings in the normal third stage of labor and 
placenta adherens (8) and went on to describe the use of ultrasound for the diagnosis of the 
three known subtypes: Placenta Adherens, Partial Accreta and Trapped Placenta (9). 
Following this description however there has been no formal analysis of the utility of 
ultrasound in RP.  
Currently, the standard treatment of RP is manual removal whatever the subtype, even though 
this has anesthetic and surgical risks. Whilst treating RP with drugs would remove many of 
these risks, medical therapies have not been well investigated, partly because of a current 
inability to rapidly and accurately distinguish the various forms of RP on the labor ward. The 
use of medical therapies to treat RP, irrespective of the underlying subtype, has led to 
confusion. 
Conflicting guidance  
1. Umbilical vein injection of oxytocin 
Following the hypothesis that the pathogenesis of the RP adherens is due to the failure of 
contraction of the retro-placental myometrium (8), umbilical vein injection (UVI) of 
oxytocics to counteract that inhibition seems to be a plausible remedy. However, conflicting 
advice on the use of UVI oxytocin to treat the RP has been issued by the National Institute of 
Health and Care Excellence (NICE) group in the UK. They recommended its use in 2007 
because of Cochrane Reviews that showed that it was associated with significantly fewer 
manual removals when compared with UVI saline (10). Now, NICE has changed its advice 
and no longer recommends the use of UVI oxytocin following a cost analysis and a finding 
that it tends to be associated with severe postpartum hemorrhage despite being an oxytocic 
(11). This is in keeping with other large controlled trials that evaluated UVI oxytocin and 
demonstrated lack of significant overall benefit including the Release Trial (6). Likewise, the 
administration of intravenous oxytocic agents to deliver a RP is not recommended unless the 
woman is bleeding excessively, although there is no conclusive evidence on this.  
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2. UVI Prostaglandins 
There is also frustration with the use of other UVI agents. Meta-analysis has demonstrated a 
significant reduction in the need for manual removal of the placenta (MROP) following UVI 
prostaglandin when compared to UVI oxytocin (10). Randomized controlled trials also 
showed that intravenous infusion of sulprostone also reduced the need for MROP when 
compared to placebo (12). However, these trials were few, with small sample sizes and their 
effects were inconsistent or statistically insignificant. Therefore, UVI Prostaglandins are 
currently not recommended.  
3. Nitroglycerin 
The use of nitroglycerine for the trapped placenta is also clouded with uncertainty. One trial 
showed sublingual nitroglycerine to be associated with a significant reduction in manual 
removal of the placenta, when compared with placebo (13). However, this trial involved only 
24 women and a subsequent larger study by the same team showed no significant benefit 
(14). Another small trial of intravenous nitroglycerine also demonstrated no benefit (15). We 
await with interest the outcome of the UK-wide randomized controlled trial on the use of 
glycerin trinitrate for the RP (GOT-IT Trial). 
Why does the optimal management of RP continue to elude us? 
It is likely that the various medical treatments for RP do not work for a number of reasons. 
The first reason is the lack of accurate diagnosis of the RP subtypes. Although RP is a group 
of pathologies, it has a common presentation and has been therefore treated as a single entity. 
It is important to get the type of RP right before prescribing uterotonics instead of relaxants. 
For, whilst uterotonics like oxytocin can treat placenta adherens by contracting the retro-
placental myometrium, they are likely to exacerbate trapped placenta by increasing cervical 
constriction. In contrast, relaxants can counteract uterine or cervical constriction to deliver a 
trapped placenta, but they would worsen placenta adherens and possibly precipitate 
hemorrhage by increasing uterine relaxation. Neither uterotonics nor relaxants can treat a 
partial accreta, but continuous cord traction on an accreta, following a false impression that a 
medication administered might help, could also lead to severe hemorrhage or uterine 
inversion.  
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The second reason may be that UVI agents probably go to the wrong place. After passing up 
the umbilical vein they perfuse through the placenta villi into the radial veins in the uterus 
without reaching the retro-placental myometrium. It is only on the second pass around the 
body that they reach the myometrial capillaries and initiate the desired myometrial 
contraction. By this stage the concentration is likely to be very low and no longer directed at 
just the retroplacental myometrium (see Figure 1).  
Conclusion 
Effective medical therapy for RP should avoid the surgical and anesthetic risks associated 
with the current standard treatment of manual removal. However it can only be made to work 
if the reasons for its failure are adequately addressed. UVI may not directly enter the 
myometrial capillary bed and alternative forms of directed treatment, possibly using 
nanoparticles, may provide a better way of delivering oxytocics to the retro-placental 
myometrium. But the main problem is our inability to differentiate between the various 
pathologies underlying RP, each of which has a different, and conflicting, treatment 
requirement.  The confusion over medical treatment will continue unless we stop treating the 
RP as a single entity and start tailoring the treatment to the underlying pathology. This will 
take an effective way of diagnosing the type – probably using a mixture of uterine ultrasound 
and Doppler of the uterine vessels. . Until then, the medical treatment of RP is likely to 
continue to elude us. 
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Legend  
Figure 1. Blood flow from umbilical veins to fetal capillaries.  
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